What does OncoTherapy Science, Inc. do?
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase…
What is OncoTherapy Science, Inc.'s P/E and P/B ratio?
OncoTherapy Science, Inc. has a P/E ratio of -7.2 and a P/B ratio of 3.24.
What is OncoTherapy Science, Inc.'s debt-to-equity ratio?
OncoTherapy Science, Inc. has a debt-to-equity ratio of 0.00.
How much does OncoTherapy Science, Inc. owe compared with what it owns?
OncoTherapy Science, Inc. owes ¥0.09 for every ¥1 it owns (balance sheet Mar 2026), which is low.
What is OncoTherapy Science, Inc.'s Positivity rank?
OncoTherapy Science, Inc. is ranked #7,825 of 10,750 companies globally and #3,323 of 3,683 in Japan on PositoAI, with a Positivity Score of 19,713.
Does OncoTherapy Science, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for OncoTherapy Science, Inc..
Where can I read the latest news about OncoTherapy Science, Inc.?
Recent headlines about OncoTherapy Science, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does OncoTherapy Science, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of OncoTherapy Science, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.